| Autor: |
Huang, Jing-Qiang, Duan, Ling-Xin, Liu, Qiu-Yu, Li, He-Feng, Hu, Ao-Ping, Song, Jun-Wei, Lin, Chuxuan, Huang, Bingsheng, Yao, Da, Peng, Bin, Sun, Yehong, Wen, Yuxin, Yang, Lin, Xu, Xingzhi, Gong, Li-Yun |
| Zdroj: |
Oncogene; April 2023, Vol. 42 Issue: 15 p1233-1246, 14p |
| Abstrakt: |
Resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a major challenge for clinicians and patients with non-small cell lung cancer (NSCLC). Serine-arginine protein kinase 1 (SRPK1) is a key oncoprotein in the EGFR/AKT pathway that participates in tumorigenesis. We found that high SRPK1 expression was significantly associated with poor progression-free survival (PFS) in patients with advanced NSCLC undergoing gefitinib treatment. Both in vitro and in vivo assays suggested that SRPK1 reduced the ability of gefitinib to induce apoptosis in sensitive NSCLC cells independently of its kinase activity. Moreover, SRPK1 facilitated binding between LEF1, β-catenin and the EGFR promoter region to increase EGFR expression and promote the accumulation and phosphorylation of membrane EGFR. Furthermore, we verified that the SRPK1 spacer domain bound to GSK3β and enhanced its autophosphorylation at Ser9 to activate the Wnt pathway, thereby promoting the expression of Wnt target genes such as Bcl-X. The correlation between SRPK1 and EGFR expression was confirmed in patients. In brief, our research suggested that the SRPK1/GSK3β axis promotes gefitinib resistance by activating the Wnt pathway and may serve as a potential therapeutic target for overcoming gefitinib resistance in NSCLC. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink